

# A Genome-Wide Association Study of Depressive Symptoms

Karin Hek, Ayse Demirkan, Jari Lahti, Antonio Terracciano, Alexander Teumer, Marilyn C. Cornelis, Najaf Amin, Erin Bakshis, Jens Baumert, Jingzhong Ding, Yongmei Liu, Kristin Marcianti, Osorio Meirelles, Michael A. Nalls, Yan V. Sun, Nicole Vogelzangs, Lei Yu, Stefania Bandinelli, Emelia J. Benjamin, David A. Bennett, Dorret Boomsma, Alessandra Cannas, Laura H. Coker, Eco de Geus, Philip L. De Jager, Ana V. Diez-Roux, Shaun Purcell, Frank B. Hu, Eric B. Rimm, David J. Hunter, Majken K. Jensen, Gary Curhan, Kenneth Rice, Alan D. Penman, Jerome I. Rotter, Nona Sotoodehnia, Rebecca Emeny, Johan G. Eriksson, Denis A. Evans, Luigi Ferrucci, Myriam Fornage, Vilmundur Gudnason, Albert Hofman, Thomas Illig, Sharon Kardia, Margaret Kelly-Hayes, Karestan Koenen, Peter Kraft, Maris Kuningas, Joseph M. Massaro, David Melzer, Antonella Mulas, Cornelis L. Mulder, Anna Murray, Ben A. Oostra, Aarno Palotie, Brenda Penninx, Astrid Petersmann, Luke C. Pilling, Bruce Psaty, Rajesh Rawal, Eric M. Reiman, Andrea Schulz, Joshua M. Shulman, Andrew B. Singleton, Albert V. Smith, Angelina R. Sutin, André G. Uitterlinden, Henry Völzke, Elisabeth Widen, Kristine Yaffe, Alan B. Zonderman, Francesco Cucca, Tamara Harris, Karl-Heinz Ladwig, David J. Llewellyn, Katri Räikkönen, Toshiko Tanaka, Cornelia M. van Duijn, Hans J. Grabe, Lenore J. Launer, Kathryn L. Lunetta, Thomas H. Mosley Jr., Anne B. Newman, Henning Tiemeier, and Joanne Murabito

**Background:** Depression is a heritable trait that exists on a continuum of varying severity and duration. Yet, the search for genetic variants associated with depression has had few successes. We exploit the entire continuum of depression to find common variants for depressive symptoms.

**Methods:** In this genome-wide association study, we combined the results of 17 population-based studies assessing depressive symptoms with the Center for Epidemiological Studies Depression Scale. Replication of the independent top hits ( $p < 1 \times 10^{-5}$ ) was performed in five studies assessing depressive symptoms with other instruments. In addition, we performed a combined meta-analysis of all 22 discovery and replication studies.

**Results:** The discovery sample comprised 34,549 individuals (mean age of 66.5) and no loci reached genome-wide significance (lowest  $p = 1.05 \times 10^{-7}$ ). Seven independent single nucleotide polymorphisms were considered for replication. In the replication set ( $n = 16,709$ ), we found suggestive association of one single nucleotide polymorphism with depressive symptoms (rs161645, 5q21,  $p = 9.19 \times 10^{-3}$ ). This 5q21 region reached genome-wide significance ( $p = 4.78 \times 10^{-8}$ ) in the overall meta-analysis combining discovery and replication studies ( $n = 51,258$ ).

**Conclusions:** The results suggest that only a large sample comprising more than 50,000 subjects may be sufficiently powered to detect genes for depressive symptoms.

**Key Words:** Center for Epidemiologic Studies Depression Scale, CHARGE consortium, depression, depressive symptoms, genetics, genome-wide association study, meta-analysis

**M**ajor depressive disorder (MDD) is a complex disease with an underlying heritable component. Family and twin studies report a high familial tendency of the disorder and heritability estimates of 31% to 42% (1,2). However, the long

From the Research Centre O3 (KH, CLM, HT), Department of Psychiatry, and Department of Epidemiology (KH, AH, MK, AGU, HT), Erasmus MC, Rotterdam, The Netherlands; Institute of Behavioural Sciences (JL, KRa), University of Helsinki, Helsinki, Finland; Clinical Research Branch (TT), National Institute on Aging, Baltimore, Maryland; Interfaculty Institute for Genetics and Functional Genomics (ATeu), University Medicine Greifswald, Greifswald, Germany; Department of Nutrition (MCC, FBH, EBR, MKJ), Harvard School of Public Health, Boston, Massachusetts; Department of Epidemiology (EB, AVD-R, SK), University of Michigan School of Public Health, Ann Arbor, Michigan; Institute of Epidemiology II (JB, RE, K-HL), Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; Department of Internal Medicine (JD), Division of Geriatrics, and Department of Epidemiology and Prevention (YL), Division of Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina; Department of Medicine (KM), Cardiovascular Health Research Unit, University of Washington, Seattle, Washington; National Institute on Aging (ATer, OM, ARS), National Institutes of Health, Department of Health and Human Services, Baltimore; and Laboratory of Neurogenetics (MAN, ABS), Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, Maryland; Department of Epidemiology (YVS), Emory University, Atlanta, Georgia; EMGO Institute for Health and Care Research (NV, BPe), and Department of Psychiatry (NV, BPe), VU University Medical Center, Amsterdam, The Netherlands; Rush Alzheimer's Disease Center (LY, DAB), and Department of Neurological Sciences (LY, DAB), Rush University Medical Center, Chicago, Illinois; Geriatric Unit Azienda Sanitaria di Firenze (SB), Firenze, Italy; National Heart, Lung, and Blood Institute's Framingham Heart Study (EJB,

search for genetic variants associated with depression has had few successes. Several linkage studies for major depressive disorder have been performed and these identified only one relevant locus (3,4). In addition, hundreds of candidate genes have been investigated in association studies, but only six variants have been confirmed in meta-analyses (5,6). Recent efforts to find new candidate genes via genome-wide association studies (GWAS) have also been largely unsuccessful (7–15). Genome-wide association studies identified interesting regions, but associations with MDD reached standard levels of genome-wide significance at only one locus (15). Furthermore, only few previously reported candidate genes were replicated in genome-wide association studies (7,13,16).

Depression exists on a continuum of varying severity and duration. Depressive symptoms (measured on a continuous scale) and MDD (measured on a dichotomous scale) are associated with

similar patterns of risk factors suggesting shared etiology with varying severity (17). The ability to detect genetic predictors might, therefore, be improved by analyzing depression quantitatively (18), defining MDD as a diagnostic entity applied to the extreme of the depression continuum (19). Using the phenotypic variation within cases and control subjects by analyzing depression quantitatively has been shown to greatly increase the power to detect genetic variants (20). In fact, a GWAS of the depression facet of personality (a continuous trait) identified several candidate genes. However, the sample size was small and findings remain to be confirmed (21).

In the current study, we exploit the entire continuum of depression, defined as the number and severity of depressive symptoms a person experiences. We assessed depressive symptoms with one of the most widely used instruments in the general population, namely the Center for Epidemiological Studies

MK-H, JMM, KLL, JM), Framingham; and Department of Medicine (EJB), Section of Cardiology and Preventive Medicine, Boston University School of Medicine and Public Health, Boston, Massachusetts; Department of Biological Psychology (DB, EdG), VU University, Amsterdam, The Netherlands; Istituto di Ricerca Genetica e Biomedica (AC, AMul, FC), Consiglio Nazionale delle Ricerche, Monserrato, Cagliari, Italy; Division of Public Health Sciences (LHC), Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Neurology (PLDJ), Program in Translational NeuroPsychiatric Genomics, Brigham and Women's Hospital, Harvard Medical School, Boston; Department of Psychiatry (SP), Massachusetts General Hospital and Harvard Medical School, Boston, and the Broad Institute, Cambridge; and Department of Epidemiology (FBH, EBR), Harvard School of Public Health, Boston, Massachusetts; Department of Biostatistics (KRI), University of Washington, Seattle, Washington; Center of Biostatistics and Department of Medicine (ADP), University of Mississippi Medical Center, Jackson, Mississippi; Medical Genetics Institute (JIR), Cedars Sinai Medical Center, Los Angeles, California; Division of Cardiology (NS), and Cardiovascular Health Research Unit (NS), Department of Medicine, University of Washington, Seattle, Washington; National Institute for Health and Welfare (JGE); Department of General Practice and Primary Health Care (JGE), University of Helsinki; Unit of General Practice (JGE), Helsinki University Central Hospital; and Folkhalsan Research Centre (JGE), Helsinki; and Vasa Central Hospital (JGE), Vasa, Finland; Department of Internal Medicine (DAE), Rush Institute for Health Aging, Rush University Medical Center, Chicago, Illinois; Longitudinal Studies Section (LF), Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland; Brown Foundation Institute of Molecular Medicine (MF), University of Texas Health Science Center at Houston, Houston, Texas; Netherlands Genomics Initiative-Sponsored Netherlands Consortium for Healthy Aging (AH, AGU, CMvD, HT), Leiden, The Netherlands; Research Unit of Molecular Epidemiology (TI), Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; Department of Neurology (MK-H), Boston University School of Medicine, Boston, Massachusetts; Department of Epidemiology (KK), Mailman School of Public Health, Columbia University, New York, New York; Department of Biostatistics (JMM), Boston University School of Public Health, Boston, Massachusetts; Epidemiology and Public Health (DM, LCP, DJL), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom; Center for Medical Systems Biology (CMvD), Leiden, The Netherlands; Institute of Biomedical and Clinical Sciences (AMur), Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom; Mental Health Center BavoEuropoort (CLM), and Department of Clinical Genetics (BAO), Erasmus MC, Rotterdam, The Netherlands; Wellcome Trust Sanger Institute (APa), Wellcome Trust Genome Campus, Cambridge, United Kingdom; Institute for Molecular Medicine Finland (APa, EW), University of Helsinki, and Department of Medical Genetics (APa), University of Helsinki and University Central Hospital, Helsinki, Finland; Program in Medical and Population Genetics and Genetics Analysis Platform (APa), The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; Department of Psychiatry (BPe), Leiden University Medical Centre, Leiden, and Department of Psychiatry (BPe), University Medical Centre Groningen, Groningen, The Netherlands; Institute of Clinical Chemistry and Laboratory Medicine (APE), University Medicine Greifswald, Greifswald, Germany; Cardiovascular Health Research Unit (BPs), Departments of Medicine, Epidemiology, and Health Services, University of Washington, and Group Health Research Institute (BPs), Group Health Cooperative, Seattle, Washington; Institute of Genetic Epidemiology (RR), Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; Neurogenomics Division (EMR), Translational Genomics Research Institute, and Banner Alzheimer's Institute (EMR), Phoenix, Arizona; Department of Psychiatry and Psychotherapy (AS, HJG), University Medicine Greifswald, Helios-Hospital, Stralsund, Germany; Laboratory of Behavioral Neuroscience (ABZ), National Institute on Aging, Baltimore, Maryland; Department of Internal Medicine (AGU), Erasmus MC, Rotterdam, The Netherlands; Institute for Community Medicine (HV), University Medicine Greifswald, Germany; Department of Psychiatry (KY), University of California San Francisco, San Francisco, California; Icelandic Heart Association (VG, AVS), Kopavogur, Iceland; Departments of Neurology (KY) and Epidemiology and Biostatistics (KY), University of California San Francisco, San Francisco, California; Laboratory of Epidemiology, Demography and Biometry (TH, LJJ), National Institute on Aging, Bethesda, Maryland; Department of Biostatistics (KLL), Boston University School of Public Health, Boston, Massachusetts; Department of Medicine (THM), University of Mississippi Medical Center, Jackson, Mississippi; Department of Medicine (JM), Section of General Internal Medicine, Boston University School of Medicine; Program in Molecular and Genetic Epidemiology (DJH, PK), Harvard School of Public Health; and Brigham and Women's Hospital (GC), Harvard Medical School, Boston, Massachusetts; Department of Epidemiology (ABN), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine (VG, AVS), University of Iceland, Reykjavik, Iceland; Hannover Unified Biobank (TI), Hannover Medical School, Hannover, Germany; College of Medicine (ATer, ARS), Florida State University, Tallahassee, Florida; Genetic Epidemiology Unit (AD, NA, BAO, CMvD), Departments of Epidemiology and Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands; and Departments of Neurology and Molecular Human Genetics (JMS), Baylor College of Medicine, Houston, Texas.

Authors KH, AD, JL, ATer, and ATeu contributed equally to this work.

Authors CMvD, HJG, LJJ, KLL, THM, ABN, HT, and JM contributed equally to this work.

Address correspondence to Henning Tiemeier, M.D., Erasmus MC, Department of Epidemiology, PO Box 2040, 3000 CA Rotterdam, The Netherlands;

E-mail: [h.tiemeier@erasmusmc.nl](mailto:h.tiemeier@erasmusmc.nl).

Received Mar 3, 2012; revised Aug 25, 2012; accepted Sep 12, 2012.

Depression (CES-D) scale. This scale assesses the following major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. The CES-D detects cases of MDD with high sensitivity and specificity (22) and has proven to be relatively stable over time (82% of older adults had stable CES-D scores over four measurement rounds in 10 years) (23,24). In addition, a high CES-D score, like a diagnosis of MDD, is associated with cardiovascular disease and mortality (25,26). Moreover, heritability estimates of depressive symptoms, as measured with the CES-D, range from 15% to 34% (27–29).

We present the results of a meta-analysis combining genome-wide association results of depressive symptoms from 17 population-based studies of European ancestry ( $n = 34,549$ ). In addition, we sought to replicate our findings in five samples that used instruments other than the CES-D to quantify depressive symptoms ( $n = 16,709$ ). Finally, we performed a combined meta-analysis of all discovery and replication studies that included 51,258 individuals.

## Methods and Materials

### Discovery Samples

This discovery set included results from 17 population-based studies comprising a total of 34,549 persons of European descent. The following studies collaborating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (30) in the United States and Europe were included: the Atherosclerosis Risk In Communities 1 and 2 studies (ARIC1 and ARIC2) (31), the Cardiovascular Health Study (CHS) (32), the Framingham Heart Study (FHS) (33,34), and the Rotterdam Study I, II, and III (RS-I, RS-II and RS-III) (35). The following population-based studies joined the discovery analyses: the Baltimore Longitudinal Study of Aging (BLSA) (36); The Erasmus Rucphen Family (ERF) (37) study; the Health, Aging and Body Composition study (Health ABC); the Invecchiare in Chianti (Aging in the Chianti area; InCHIANTI) (38) study; Helsinki Birth Cohort Study (HBCS) (39); Multi-Ethnic Study of Atherosclerosis (MESA) (40); Nurses' Health Study (NHS) (41); Rush Memory and Aging Project (MAP) (42); Religious Orders Study (ROS) (43), and SardiNIA study (44). All studies were approved by their local institutional review boards and all participants provided written informed consent.

### Phenotype Definition

Depressive symptoms were measured with the CES-D scale (10-item version [CHS, NHS, Rush MAP, Rush ROS], 11-item version [ARIC1], or 20-item version [ARIC2, BLSA, ERF, FHS, HBCS, Health ABC, InCHIANTI, MESA, RS-I, RS-II, RS-III, SardiNIA]). The CES-D scale is designed for use in the general population. All three CES-D versions used here detect the same four latent factors (45): depressed affect, somatic symptoms, positive affect, and interpersonal problems. Each item is scored from 0 to 3 depending on the frequency of the symptoms during the past week. A higher score corresponds to more depressive symptoms. Scores from one examination round per study were used, but CES-D scores have been shown to be relatively stable over time (23,24). In studies with multiple CES-D assessments, the round with the largest number of participants (generally the first examination round) was chosen. Persons with schizophrenia or bipolar disorder were excluded, based on records, interviews, or medication use (these disorders probably have a distinct genetic

component). In addition, persons with a Mini-Mental State Examination score  $< 22$ , indicative of dementia, were excluded. We included persons with genotype data and depressive symptom score who were aged 40 years and older.

### Adjustment for Use of Antidepressants

In the search for common variants for depressive symptoms in a population-based sample, persons using antidepressants, who most likely had depression or depressive symptoms, increase genetic information. We, thus, did not exclude these persons from the analysis, but we chose to adjust their total depressive symptoms score for medication use. However, response to antidepressants is highly variable. In addition, information on compliance is often not available in population-based studies. We therefore used a nonparametric imputation algorithm to adjust the CES-D score for treatment effect. We made two assumptions: the CES-D score of a person using antidepressants is a right-censored value, i.e., the score is lower than the untreated value would be; and persons with a high CES-D score, on average, responded less to their medication than persons with a lower CES-D score. We replaced the score of a person on antidepressants with the mean depressive symptom score of all persons using antidepressants that had the same or a higher depressive symptom score. This procedure was performed separately for men and women and was based on an algorithm used for adjustment of blood pressure for persons on antihypertensive drugs (46). Antidepressant medication was defined by each study separately to account for differences between countries.

### Genotyping and Imputation

Genome-wide genotyping was performed by the individual studies on Illumina (Illumina, Inc., San Diego, California) or Affymetrix (Affymetrix, Santa Clara, California) platforms. All studies imputed their genotype data to  $\sim 2.5$  million single nucleotide polymorphisms (SNPs) to account for the different genotyping platforms. HapMap release 22 CEU (HapMap sample comprised of Utah residents with Northern and Western European ancestry) build 36 was generally used as reference for imputation (two studies used build 35). Genotype and imputation quality control were performed in each study separately. Genotype and quality control procedures for each study can be found in Table S1 in Supplement 1.

### Data Analysis

A linear regression was performed on total depressive symptom score, adjusted for age and gender. The distribution of CES-D scores is skewed, but linear regression is fairly robust to nonnormality. Cardiovascular Health Study and Atherosclerosis Risk In Communities additionally adjusted for field study site, NHS for disease status, SardiNIA for self-report versus tester-read and reported answers, and FHS for cohort (offspring, generation 3). Furthermore, FHS used linear mixed effect models to account for familial correlations. In the ERF study, kinship matrix was used to correct for relatedness.

### Meta-Analysis

We performed a  $p$  value based meta-analysis weighted by sample size. This is a valid approach to account for the different CES-D versions to measure depressive symptoms and for the

different distributions of depressive symptoms. The meta-analysis test statistic was computed as follows:

$$Z_{meta} = \sum_i \frac{\beta_i}{SE_i} \times \sqrt{\frac{N_i}{N_{total}}}$$

The meta-analysis was performed with METAL (<http://www.sph.umich.edu/csg/abecasis/metal/>) (47). The beta ( $\beta$ ) of each individual study  $i$  was matched to a common coded allele (the minor allele) for each SNP across all studies. Single nucleotide polymorphisms with a minor allele frequency less than 2.5% or an observed to expected variance ratio (imputation quality) less than .30 were excluded on a per study basis. Single nucleotide polymorphisms for which the total sample size was lower than 5000 were removed from the results. Genomic control correction was applied to each study's results.

### Replication

Independent top SNPs with a  $p$  value  $< 1 \times 10^{-5}$  in the discovery meta-analysis were selected with the clumping function in PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>) (48) ( $R^2 < .05$ , 500 kilobase [kb]) for replication in five studies that measured depressive symptoms with other instruments (total  $n = 16,709$ ). Persons included in the replication studies were independent from those in the discovery studies. Although replication with other instruments than the CES-D might introduce some heterogeneity, all instruments measure depressive symptoms. Further, a positive replication would ensure that our top hits are not instrument-dependent.

Age, Gene, Environment Susceptibility–Reykjavik Study (AGES) (49), the ARIC 3 study (31), Monitoring of Trends and Determinants of Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg F3 and F4 (MONICA/KORA F3 and F4) (50), and the Study of Health in Pomerania (SHIP) (51,52) measured depressive symptoms with the Geriatric Depression Scale (GDS), Maastricht Questionnaire, Patient Health Questionnaire (PHQ-9), and the Beck Depression Inventory-II (BDI-II), respectively. The BDI-II, GDS, and PHQ-9 aim to screen for depression and are highly correlated (53,54). The BDI-II is based on the DSM-IV criteria for MDD and comprises 21 items on a scale of 0 to 3 with higher scores indicating more severe depressive symptoms over the past 2 weeks. The PHQ-9 is, like the BDI-II, based on the DSM-IV criteria for MDD, but it consists of nine items on a scale of 0 to 3 to assess depressive symptoms over the past 2 weeks. The GDS was specifically designed to screen for depression in older adults and comprised 15 items answered with “yes” or “no.” The Maastricht Questionnaire (21 items), although designed to measure vital exhaustion, correlates with measures of depressive symptoms (55) and was previously used to assess depressive symptoms (56,57).

Replication was considered significant if the Bonferroni-corrected  $p$  value for testing seven SNPs was  $\leq .050$  (uncorrected  $p$  value  $\leq 7.1 \times 10^{-3}$ ).

### Pathway Analysis

Protein ANalysis THrough Evolutionary Relationships (PANTHER) (58) was used to identify and classify biological processes among the SNPs associated with  $p$  values  $< 10^{-4}$  from the overall meta-analysis ( $n = 51,258$ ). After SNP selection, SNPs were annotated to genes and/or flanking genes with the SCAN SNP and CNV Annotation Database (<http://www.scandb.org>). Protein ANalysis THrough Evolutionary Relationships then compares this gene list to a reference list (Homo Sapiens gene list from the National Center for Biotechnology Information) using the

binomial test. Results were Bonferroni-corrected to account for multiple testing.

### Candidate Gene Search

Altogether, 17 SNPs previously reported to be associated to depression were selected: 1 SNP that has been found genome-wide significantly associated with depressive phenotypes after replication (7,59), 4 top SNPs from the largest MDD meta-analysis so far (13), and 12 top SNPs from the only published GWAS that studied a depressive trait continuously (21). Single nucleotide polymorphisms were tested for association in the discovery meta-analysis ( $n = 34,549$ ) and in the overall meta-analysis including all studies that measured depressive symptoms ( $n = 51,258$ ).

## Results

### Meta-Analysis of Depressive Symptoms

Table 1 shows the characteristics of the study populations. Mean age in the discovery studies ranged between 55.9 and 80.8 years. The percentage of women varied between 44.6% and 100%. In line with the population-based design of the studies, median depressive symptoms scores ranged between 2 and 10 for the CES-D 20-item version. This is well below the cutoff of 16 at which major depression cases in older adults can be identified with high specificity and sensitivity (22). The percentage of persons scoring above this cutoff varied between 4.7% and 27.1%. Distributions of CES-D scores differed between studies and therefore a Z-score based meta-analysis was used to combine the individual study results. Antidepressant use ranged from 3.0% to 14.0%. On average, CES-D scores for persons on antidepressants more than doubled after imputation.

The genomic control inflation factor lambda ( $\lambda_{gc}$ ) for each study ranged between .997 and 1.024. A meta-analysis of 17 studies ( $n = 34,549$ ) with depressive symptoms measured by CES-D was performed (Q-Q and Manhattan plots in Figure S1 in Supplement 1). The total number of SNPs analyzed was 2,391,896. No association reached the prespecified genome-wide significance level of  $5 \times 10^{-8}$  for the association with the depressive symptom score. However, we identified 117 SNPs with a  $p$  value  $< 1 \times 10^{-5}$ , which included seven independent top SNPs ( $R^2 < .05$  in 500 kb, Table 2). The SNP with the lowest  $p$  value was rs8020095 ( $p = 1.05 \times 10^{-7}$ ) and maps to an intronic region of *GPHN* on chromosome 14. Of the seven top SNPs, none had a heterogeneity  $p$  value (tested by Cochran's Q) below .05 in the discovery meta-analysis.

We reran the analysis for the independent top SNPs excluding people on antidepressants;  $p$  values of the top SNPs shifted toward one (e.g., rs8020095  $p$  value  $1.56 \times 10^{-6}$ , rs161645  $p$  value  $1.71 \times 10^{-3}$ ). Adding five points to the total score for people using antidepressants in a subsample (RS-I, RS-II, RS-III,  $n = 7925$ ) resulted in the same top SNPs and similar  $p$  values for the top SNPs tested here.

### Replication

Table 2 presents the results of the replication analysis and the overall meta-analysis across discovery sample and replication sample. The mean observed to expected variance ratio for the seven top SNPs across all cohorts ranged between .91 and .98 (Table S2 in Supplement 1). In the replication sample, an SNP on chromosome 5 showed an association with depressive symptoms (5q21, rs161645,  $p = 9.19 \times 10^{-3}$ , Table 2), but this association

**Table 1.** Study Sample Characteristics of Discovery and Replication Samples

Sample	Instrument	<i>n</i>	Depressive Symptom Score					Antidepressant Users %	Mean Age	(SD)	Female %	Current Smokers %	International Standard Classification of Education <sup>b</sup>				
			Mean	(SD)	Median	(Range)	≥16 % <sup>a</sup>						Level 0/1 %	Level 2 %	Level 3 %	Level 4 %	Level 5/6 %
Discovery Studies ( <i>n</i> = 34,549)																	
ARIC1	CES-D 11	393	3.80	(3.57)	3	(0–18)	9.92	14.0	72.7	(5.46)	59.5	19.6	2.0	8.1	35.4	7.9	46.6
ARIC2	CES-D 20	614	8.52	(7.41)	6	(0–34)	16.1	11.1	71.0	(5.60)	49.7	19.7	3.1	8.3	34.7	11.7	42.2
BLSA	CES-D 20	764	6.90	(6.5)	5	(0–55)	8.51	NA	71.6	(13.8)	44.6	3.0	.4	1.5	11.0	12.4	74.8
CHS	CES-D 10	3155	4.27	(4.29)	3	(0–26)	11.3	3.11	72.2	(5.29)	61.2	11.0	2.5	12.3	38.6	9.3	37.2
ERF	CES-D 20	1297	12.7	(10.9)	10	(0–59)	27.1	8.20	55.9	(10.1)	56.7	43.2	40.4	42.5	13.6	NA	3.5
FHS	CES-D 20	4956	7.25	(8.21)	4	(0–53)	10.3	10.4	56.1	(10.5)	53.3	14.7	.5	3.1	32.2	24.9	39.2
HABC	CES-D 20	1654	4.93	(5.78)	3	(0–43)	4.70	3.60	73.8	(2.80)	47.1	6.4	11.9	NA	34.4	53.6	NA
InCHIANTI	CES-D 20	942	11.8	(8.24)	10	(0–46)	24.6	3.40	70.4	(9.85)	52.8	18.5	73.5	11.2	7.3	4.6	3.4
RSI	CES-D 20	3791	4.86	(7.35)	2	(0–52)	7.30	3.80	72.7	(7.21)	58.5	16.4	31.4	29.0	29.8	NA	9.8
RSII	CES-D 20	2093	5.81	(7.90)	3	(0–48)	9.70	5.00	64.8	(8.03)	54.5	19.6	21.6	35.6	27.1	NA	15.7
HBSC	CES-D 20	1386	9.58	(8.68)	7	(0–53)	19.4	4.70	63.4	(2.86)	59.7	23.0	33.0	18.4	26.0	NA	22.5
MESA	CES-D 20	2423	6.93	(6.87)	5	(0–50)	10.0	12.2	62.7	(10.2)	52.2	11.4	1.6	3.4	16.5	28.4	50.1
NHS	CES-D 10	5891	6.36	(4.50)	6	(0–26)	15.9	13.3	71.7	(6.70)	100	5.5	0	0	0	72.6	27.4
RSIII	CES-D 20	2041	6.32	(8.22)	3	(0–53)	9.90	6.90	56.0	(5.67)	56.1	22.4	9.8	35.0	28.4	NA	26.8
Rush MAP	CES-D 10	825	1.38	(1.75)	1	(0–8)	20.1	13.6	80.8	(6.53)	73.0	2.4	1.7	27.4	19.9	42.8	8.2
Rush ROS	CES-D 10	778	1.10	(1.51)	1	(0–8)	13.9	9.00	75.5	(7.24)	66.5	2.1	1.3	5.4	3.1	46.0	44.2
SardinIA	CES-D 20	1438	11.9	(8.20)	10	(0–53)	25.2	3.00	58.0	(11.4)	59.5	NA	28.9	50.3	16.1	NA	4.8
Replication Studies ( <i>n</i> = 16,709)																	
AGES-RS	GDS	2855	2.58	(2.26)	2	(0–15)	9.92	13.8	76.4	(5.46)	58.0	12.7	22.1	16.8	NA	33.3	27.8
ARIC3	MQ	8918	10.2	(8.79)	8	(0–42)	9.39	4.04	57.2	(5.67)	52.7	23.8	4.8	10.2	36.4	9.2	39.4
MK F3	PHQ-9	1433	3.52	(3.54)	3	(0–26)	6.80	NA	60.5	(9.13)	51.3	14.3	12.1	56.4	17.6	.8	13.1
MK F4	PHQ-9	1807	3.36	(3.3)	3	(0–27)	5.50	NA	60.9	(8.85)	51.5	14.6	10.0	52.4	22.6	1.1	14.0
SHIP	BDI-II	1696	6.44	(7.11)	4	(0–58)	8.90	NA	59.4	(11.6)	51.4	25.5	5.1	.3	60.4	15.9	18.4

ARIC1, ARIC2, ARIC3, RSI, RSII, RSIII, MK F3, and MK F4 included unique individuals.

AGES-RS, Age, Gene, Environment Susceptibility–Reykjavik Study; ARIC, Atherosclerosis Risk in Communities study; BDI-II, Beck Depression Inventory-II; BLSA, Baltimore Longitudinal Study of Aging; CES-D, Center for Epidemiologic Studies Depression scale; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family study; FHS, Framingham Heart Study; GDS, Geriatric Depression Scale; HABC, Health, Aging and Body Composition study; HBSC, Helsinki Birth Cohort Study; InCHIANTI, Invecchiare in Chianti; MESA, Multi-Ethnic Study of Atherosclerosis; MK, Monitoring of trends and determinants of cardiovascular disease/cooperative health research in the region of Augsburg (MONICA/KORA); MQ, Maastricht Questionnaire; NA, not applicable; NHS, Nurses Health Study; PHQ-9, Patient Health Questionnaire-9 items; RS, Rotterdam Study; Rush MAP, Rush Memory and Aging Project; Rush ROS, Rush Religious Orders Study; SardinIA, SardinIA study; SHIP, Study of Health In Pomerania; SD, standard deviation.

<sup>a</sup>Cutoff for screen positives was 9 for ARIC1, 8 for CHS, 9 for NHS, 3 for Rush MAP and Rush ROS, 6 for AGES-RS, 24 for ARIC3, and 17 for SHIP.

<sup>b</sup>Level 0: preprimary education; level 1: primary education or first stage of basic education; level 2: lower secondary education or second stage of basic education; level 3: (upper) secondary education; level 4: postsecondary nontertiary education; level 5: first stage of tertiary education; level 6: second stage of tertiary education.

**Table 2.** Meta-Analysis Results of CES-D Depressive Symptom Score in Discovery Studies, Replication of Results in Studies that Measured Depressive Symptoms with Other Instruments, and Overall Meta-Analysis of All Studies

SNP <sup>a</sup>	Chr	Position	SNPs (n) <sup>b</sup>	Closest Gene	Distance (Base Pair)	Allele	MAF	Discovery Meta-Analysis CES-D n = 34,549		Replication Other Instruments n = 16,709		Overall Meta-Analysis n = 51,258	
								Overall Direction (Per Study)	p Value	Overall Direction (Per Study)	p Value	Overall Direction	p Value
rs8020095	14	66,523,611	2	<i>GPHN</i>	intron	A/G	.17	+ (+++++-----+-----+?)	1.05e-07	- (-?---+)	.79	+	3.04e-06
rs8038316	15	52,560,732	3	<i>UNC13C</i>	intron	A/G	.05	- (-?-----+-----+)	1.24e-06	- (----+)	.42	-	9.64e-06
rs161645	5	104,097,816	3	<i>NUDT12</i>	1,171,427	A/G	.34	+ (+++++-----+-----+?)	2.32e-06	+ (+++--+)	9.19e-03	+	8.39e-08 <sup>c</sup>
rs357282	5	38,904,792	0	<i>OSMR</i>	intron	T/G	.13	+ (+++++-----+-----+)	7.56e-06	+ (-+---+)	.87	+	1.60e-04
rs4653635	1	223,662,313	3	<i>LBR</i>	intron	A/G	.16	- (----+-----+-----)	8.14e-06	+ (-+---)	.55 <sup>d</sup>	-	8.89e-04
rs4594522	20	30,718,645	5	<i>COMMD7</i>	35,508	C/T	.36	- (----+-----+-----+)	9.29e-06	- (-+---)	.80	-	1.56e-04
rs13137117	4	94,673,387	9	<i>GRID2</i>	intron	T/A	.25	+ (+++++-----+-----+)	9.77e-06	+ (-+---)	.97	+	2.63e-04

Direction of effect discovery: Framingham Heart Study, Cardiovascular Health Study, Rotterdam Study-I/Rotterdam Study-II/ Rotterdam Study-III, Atherosclerosis Risk in Communities1, Atherosclerosis Risk in Communities2, Erasmus Rucphen Family study, Invecchiare in Chianti, Health, Aging and Body Composition, Baltimore Longitudinal Study of Aging, Helsinki Birth Cohort Study, Multi-Ethnic Study of Atherosclerosis, Nurses' Health Study (NHS)-breast cancer substudy, NHS-cardiovascular health disease substudy, NHS-kidney stones substudy, NHS-type 2 diabetes substudy, Rush-Memory and Aging Project, Rush-Religious Orders Study, and SardiNIA study. Direction of effect replication: Age, Gene, Environment Susceptibility-Reykjavik Study, Atherosclerosis Risk in Communities3, Monitoring of trends and determinants of cardiovascular disease/cooperative health research in the region of Augsburg (MONICA/KORA) F3, MONICA/KORA F4, and Study of Health In Pomerania. Allele = minor/major on the + strand, the minor allele is the coded allele.


?, not tested; CES-D, Center for Epidemiologic Studies Depression scale; Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism.

<sup>a</sup>Independent SNPs with a  $p$  value  $< 1 \times 10^{-5}$  in the discovery meta-analysis. The total  $n$  for SNP rs8020095 was 40,902, for rs8038316 was 48,103, for rs161645 was 49,820, and for the other SNPs was 51,258. The mean observed versus expected variance ratio (measure of imputation quality) for imputed SNPs ranged between .91 and .99. Table S2 in Supplement 1 includes this information detailed per SNP.

<sup>b</sup>Supporting SNPs: number of SNPs in linkage disequilibrium with the top SNP ( $R^2 > .8$ ), with a  $p$  value  $< 10^{-4}$ .

<sup>c</sup>Lowest  $p$  value of the overall meta-analysis  $p = 4.78 \times 10^{-8}$  for SNP rs40465 (G/T) that is in linkage disequilibrium ( $R^2 = .80$ ) with rs161645, discovery  $p = 2.58 \times 10^{-6}$  (+++++-----+-----+?), replication  $p = 5.00 \times 10^{-3}$  (+++--+).

<sup>d</sup>Heterogeneity  $p$  value  $< .05$ .



**Figure 1.** Association results in the 5q21 region. Summary of the association of single nucleotide polymorphisms (SNPs) on chromosome 5 (base 103,500,000 to 104,500,000) with depressive symptoms from the overall meta-analysis ( $n = 51,258$ ). The SNP with the strongest association (rs40465) is highlighted in blue and its corresponding  $p$  value is given. Other SNPs are colored according to their degree of linkage disequilibrium (LD) with rs40465, ranging from high LD (orange,  $R^2 = .5-1.0$ ) to low LD (white,  $R^2 < .2$ ). cM, centimorgan; kb, kilobase; Mb, megabase.

did not reach the predefined threshold for multiple testing (corrected for multiple testing  $p = .064$ ). This SNP resides in a gene desert, with the closest gene *NUDT12* more than 1000 kb away.

In the overall meta-analysis including discovery and replication samples ( $n = 51,258$ ), SNP rs40465 reached genome-wide significance ( $p = 4.78 \times 10^{-8}$ ). This SNP is in high linkage disequilibrium with SNP rs161645 ( $R^2 = .80$ ). Rs40465 had a  $p$  value of  $2.58 \times 10^{-6}$  in the discovery meta-analysis and a  $p$  value of  $5.00 \times 10^{-3}$  in the meta-analysis of replication studies. An association plot of the 5q21 region is presented in Figure 1.

In contrast, the strength of the associations of the other top SNPs with depressive symptoms was attenuated, as judged by the  $p$  value. All SNPs with a  $p$  value  $< 1 \times 10^{-4}$  from the overall meta-analysis ( $n = 51,258$ ) are presented in Table S3 in Supplement 1.

### Pathway Analysis

One hundred four functional genes of the 170 genes that were annotated were mapped to biological processes. Relevant processes that were overrepresented among top SNPs ( $p$  value  $< 10^{-4}$ ) of the overall meta-analysis were neurotransmitter secretion (Bonferroni-corrected  $p$  value =  $9.84 \times 10^{-3}$ ), vitamin transport (Bonferroni-corrected  $p$  value = .014), and synaptic transmission (Bonferroni-corrected  $p$  value = .037). A complete list of biological processes that were significantly overrepresented is presented in Table 3.

### Candidate Gene Search

None of the 17 tested candidate genes were replicated in the current study (Table S4 in Supplement 1). Nine out of 17 associations had the same direction in our overall meta-analysis as in the published study, and none of the nine was significant (uncorrected for multiple testing).

### Discussion

In this GWAS of depressive symptoms, we combined the results of 17 population-based studies with 34,549 individuals to find common variants for depressive symptoms. Including the

**Table 3.** Pathway Analysis

Biological Process	NCBI	Observed	Expected	Over/ Under	Adjusted $p$ Value <sup>a</sup>
Neurotransmitter Secretion	346	6	1.81	+	9.84e-03
Vitamin Transport	95	3	.50	+	.014
Protein Metabolic Process	3240	26	16.92	+	.015
Synaptic Transmission	594	7	3.10	+	.037
Transport	2857	22	14.92	+	.038
Vesicle-Mediated Transport	1160	11	6.06	+	.040
Cation Transport	621	7	3.24	+	.045
Cell-Cell Signaling	1331	12	6.95	+	.045
Protein Transport	1646	14	8.60	+	.048
Intracellular Protein Transport	1646	14	8.60	+	.048

Enrichment of biological processes among the top results (overall meta-analysis  $p$  value  $< 10^{-4}$ ) was statistically tested with a binomial test.

NCBI: number of genes in a biological process (reference). Observed: number of genes that belong to a biological process among the GWAS results. Expected: expected number of genes that belong to a biological process in the GWAS results. Over/under: overrepresentation or underrepresentation of the genes in the results.

GWAS, genome-wide association studies; NCBI, National Center for Biotechnology Information.

<sup>a</sup>A Bonferroni-correction was applied to correct for multiple testing.

five replication studies, this effort comprised data from 51,258 independent individuals. Of the seven SNPs we attempted to replicate, we found suggestive evidence for the observed association of one SNP in the 5q21 region with depressive symptoms. This region reached genome-wide significance when tested over all studies ( $n = 51,258$ ).

Although evidence shows that depression can be well represented by a continuum of depressive symptoms, we observed a genome-wide significant hit in this large GWAS only when pooling all studies with depressive symptoms. This difficulty of finding signals is in line with GWAS of major depression. Nine GWAS of depression, of which the largest comprised  $\sim 6000$  MDD cases and  $\sim 7000$  control subjects, yielded only one genome-wide significant finding (15).

The approach of studying depression on a continuum has the advantage that not only information on extremes is used but that all available information is exploited. Van der Sluis *et al.* (20) showed that if the phenotypic variation among cases, as well as the variation among control subjects, is used, this greatly increases the power to detect genetic variants. However, studying depression along a continuum in population-based studies implies that many individuals have a low depressive symptoms score and that few persons score high. Therefore, it remains to be validated whether the results presented here are generalizable to clinical depression cases. In addition, the CES-D measures current depressive symptoms and not remitted depressive symptomatology. This introduces false-negatives, but in this population-based approach in which low depressive symptomatology is overrepresented, the resulting bias would be conservative. Furthermore, the distribution of depressive symptoms differed between cohorts. We therefore performed a  $p$  value based meta-analysis, which is a valid approach, but has the consequence that we cannot draw conclusions on effect sizes.

Differences in depressive symptoms distribution do not impact on the validity of the findings. People with high depressive symptoms are more likely to carry risk variants, but this should not depend on the number of people with a high score. Furthermore, the distribution of  $I^2$ , a measure of heterogeneity (60), of the results combining all samples did not differ from the distribution of  $I^2$  of the results when samples with low or high depression prevalence were meta-analyzed separately. No excess heterogeneity was observed, which suggests that depressive symptoms can be analyzed linearly. However, some genetic main effects may be more detectable in very homogeneous populations. Observed differences in distributions of depressive symptoms may have resulted from environmental factors, and if these, in turn, interact with specific genetic variants, only very homogeneous studies could also detect a genetic main effect.

Environmental factors, like education level, differed among cohorts. In observational research, one would have controlled for such possible confounders. In genetic studies, confounding by environmental factors is unlikely to occur (61), but controlling for environmental factors can also be done to increase precision, i.e., reduce the variance in depressive symptoms (62). However, environmental factors explain very little variance in depressive symptoms. Therefore, the benefit of performing additional controlled analyses will be negligible and offset by running several models with the risk of multiple testing.

In the current study, depressive symptom scores for people using antidepressants were imputed to take into account the high variability in response to antidepressants. In an analysis of depressive symptoms, people on antidepressants, who most likely had depression or depressive symptoms, are particularly informative. Therefore, excluding this group a priori may have changed the results. In a subsample, the imputation algorithm used in the current study yielded similar results as adding an arbitrary score of five points to the depressive symptom scores of people using antidepressants.

This study was performed in older adults. Cerebrovascular burden and cognitive impairment, which have a relatively high prevalence in old age, are known to be associated with depressive symptoms. In addition, while a high CES-D score indicates depressive symptoms, it can also be suggestive of, for example, anxiety (63). In other words, the level of depressive symptoms is a clinically heterogeneous phenotype. However, the genetic background of clinically heterogeneous phenotypes like anxiety and depression may be more uniform than the clinical presentation suggests (64). In addition, while nongenetic determinants of depression may differ with age, genetic determinants were shown to be stable at different ages (65,66). Therefore, the results presented here are presumably generalizable to younger populations.

We combined results from studies that measured depressive symptoms with instruments other than the CES-D to replicate the association between depressive symptoms and seven independent top SNPs. In an overall meta-analysis, we tested whether any variation introduced by different instruments was offset by the increased power. In the replication effort, one SNP (5q21 region) reached a  $p$  value below .05 but did not pass this threshold when controlling for multiple testing. Another SNP in the 5q21 region, however, reached genome-wide significance when the association across discovery and replication studies was tested ( $n = 51,258$ ). The 5q21 region resides in a gene desert with the closest gene, *NUDT12*, lying more than 1000 kb away. *NUDT12* has not been previously implicated in psychiatric disorders.

Although we observed suggestive association of the 5q21 region with depressive symptoms, genome-wide significance

was observed only after pooling the results of the discovery and replication studies. Also, we could not replicate associations with candidate genes that previously have been reported to be associated with depression. Several explanations are plausible.

A first explanation for these observations is that the top SNPs identified in this study are false-positive findings. However, the discovery set was large and although we did not find any genome-wide significant hits, true hits are expected to be found among the top findings. A pathway analysis on the results of the overall meta-analysis showed that biological processes that play a role in depression were overrepresented among our top hits.

Second, the replication sample was smaller than the discovery sample and may be underpowered to detect true effects with moderate effect sizes, which might have been overestimated in the discovery analysis (winner's curse). Indeed, we found suggestive evidence of association for only one of seven SNPs, but the direction of association was compatible for five out of seven SNPs.

Third, lack of replication might be related to heterogeneity of the replication phenotype. In the replication approach, we combined the results of studies that measured depressive symptoms with different instruments. Instruments were also administered at different time points across studies. However, the instruments have been reported to be highly correlated (correlations between .77 and .86) and relatively stable genetic determinants over the life span were observed in an Australian Twin study (53,54,65,67,68).

Several other factors can hinder the search for common variants associated with depressive symptoms. Population stratification, for example, can result in false-positive findings. To avoid population stratification, only individuals from European descent were included. Including only individuals from European descent also minimized measurement error caused by cultural differences in responses to the CES-D (69). Other possible explanations are the presence of genetic heterogeneity (70), gene-gene interactions (71), and gene-environment interactions. The interaction between candidate genes and life events has been repeatedly studied for depression (72). However, to study this phenomenon in a genome-wide approach requires much larger data sets (13). In addition, it is suggested that the gain of gene-environment interaction studies over studies of main effects for complex diseases like depression is minimal (73). The study described here focused on common genetic variation, but rare variants or copy number variations not tagged by SNPs might play a role in depression (74,75). Using a larger reference panel, like the haplotypes generated by the 1000 Genomes Project, would have improved the yield of rare variants. Harmonizing imputation reference and imputation tools might have further increased the power of the study to detect associations. Also, not single SNPs, but many SNPs collectively, each with a very small effect, may affect the susceptibility for depressive symptoms (66).

In conclusion, the efforts of a large collaboration to identify common variants associated with depressive symptoms yielded no genome-wide significant hit in the discovery sample. In the replication approach, we found suggestive evidence for a SNP in the 5q21 region. When analyzing the discovery and replication samples, one genome-wide significant hit in this region was observed. Further investigation of the 5q21 region is necessary to verify the association with depressive symptoms and to pinpoint the possible functional variant. Such a future study of depressive symptoms could analyze this phenotype stratified by gender and incorporate longitudinal information with repeated measures of



depressive symptoms to provide more power to our search for potential candidate genes.

We acknowledge the essential role of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium in development and support of this manuscript. Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium members include the Netherland's Rotterdam Study, the National Heart, Lung, and Blood Institute's (NHLBI) Framingham Heart Study, Cardiovascular Health Study, the NHLBI's Atherosclerosis Risk in Communities Study, and the National Institute on Aging's (NIA) Iceland Age, Gene/Environment Susceptibility Study.

The Age, Gene/Environment Susceptibility Reykjavik Study has been funded by National Institutes of Health (NIH) contract N01-AG-12100, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament).

The Atherosclerosis Risk in Communities Study research is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022 and Grants R01-HL087641, R01-HL093029, and R01-HL70825; National Human Genome Research Institute contract U01-HG004402; and National Institutes of Health contract HHSN268200625226C. We thank the staff and participants of the Atherosclerosis Risk in Communities Study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.

The Baltimore Longitudinal Study of Aging research was supported entirely by the Intramural Research Program of the NIH, National Institute on Aging.

This Cardiovascular Health Study research was supported by NHLBI contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133 and NHLBI Grants HL080295, HL075366, HL087652, and HL105756 with additional contribution from National Institute of Neurological Disorders and Stroke. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also <http://www.chs-nhlbi.org/pi.htm>. DNA handling and genotyping was supported, in part, by Clinical and Translational Science Institute Grant UL1RR033176 to the Cedars-Sinai General Clinical Research Center Genotyping core, National Institute of Diabetes and Digestive and Kidney Diseases Grant DK063491 to the Southern California Diabetes Endocrinology Research Center, and the Governors' Chair in Medical Genetics (JIR).

The Erasmus Rucphen Family (ERF) research was supported through funds from The European Community's Seventh Framework Programme (FP7/2007-2013), European Network for Genetic and Genomic Epidemiology Consortium, Grant agreement HEALTH-F4-2007- 201413.

The genotyping for the ERF study was supported by European Special Populations Research Network and the European Commission FP6 STRP Grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by Grants from the Netherlands Organisation for Scientific Research, Erasmus MC, the Centre for Medical Systems Biology, and the Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all participating individuals and their relatives, general practitioners, and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work, and P. Snijders for his help in data collection.

Framingham Heart Study: The phenotype-genotype association analyses were supported by R01-AG29451. "This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart Lung and Blood Institute of

the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource project. This work was partially supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center."

Helsinki Birth Cohort Study has been supported by Grants from the Academy of Finland, the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, European Science Foundation (EUROSTRESS), Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation, and Wellcome Trust (Grant number WT098051). We thank all study participants, as well as everybody involved in the Helsinki Birth Cohort Study.

The Health, Aging and Body Composition research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA Grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research. Center for Inherited Disease Research is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported, in part, by the Intramural Research Program of the NIH, National Institute on Aging. Dr. Yaffe is supported by NIH Grant R01 MH086498.

The Invecchiare in Chianti Study was supported as a targeted project (ICS 110.1RS97.71) by the Italian Ministry of Health, by the U.S. National Institute on Aging (Contracts N01JAG916413, N01JAG 821336, 263 MD 9164 13, and 263 MD 821336), and, in part, by the Intramural Research Program, National Institute on Aging, National Institutes of Health.

The Multi-Ethnic Study of Atherosclerosis (MESA) SNP Health Association Resource project is conducted and supported by the NHLBI in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159 through N01-HC-95169 and UL1-RR-024156. Funding for genotyping was provided by NHLBI Contract N02-HL-6-4278 and N01-HC-65226. Funding for this project was also provided by #R01 HL101161.

The Monitoring of Trends and Determinants of Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany, and supported by Grants from the German Federal Ministry of Education and Research. Furthermore, the research was supported within the Munich Center of Health Sciences as part of Ludwig-Maximilians-University.

The Nurses' Health Studies are supported by NIH Grants CA 65725, CA87969 (National Cancer Institute), CA49449, CA67262, CA50385, and 5U01CA098233.

The generation and management of genome-wide association study genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research Investments (number 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015), the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research project number 050-060-810. The Rotterdam Study is funded by Erasmus MC and Erasmus University, Rotterdam,

Netherlands Organization for the Health Research and Development, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (Directorate-General XII), and the Municipality of Rotterdam. Henning Tiemeier was supported by the Vidi Grant of Netherlands Organization for the Health Research and Development (2009-017.106.370). Karin Hek was supported by a Grant from BavoEuroport. We are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters for their help in creating the genome-wide association study database, and Dr. Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. We thank Dr. Karol Estrada, Dr. Fernando Rivadeneira, Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob de Graaf (Erasmus MC Rotterdam, The Netherlands) for their help in creating GRIMP and BigGRID, MediGRID, and Services@MediGRID/D-Grid (funded by the German Bundesministerium für Forschung und Technologie; Grants 01 AK 803 A-H, 01 IG 07015 G) for access to their grid computing resources.

The Rush Memory and Aging Project is supported by NIA Grants R01AG15819, R01AG17917, and K08AG34290 and the Translational Genomics Research Institute. The Rush Religious Orders Study is supported by NIA Grants P30AG10161, R01AG15819, R01AG30146, and K08AG34290 and the Translational Genomics Research Institute. We thank the study participants and the staff of the Rush Alzheimer's Disease Center. Joshua Shulman was additionally supported by a Career Award for Medical Scientists from Burroughs Wellcome Fund.

The SardiNIA research was supported, in part, by the Intramural Research Program of the NIH, National Institute on Aging. Funding was also provided through contract NO1-AG-1-2109 from the NIA-NIH.

Study of Health in Pomerania is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs, and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant no. 03ZIK012) and a joint Grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Center of Knowledge Interchange program of the Siemens AG. This work was also funded by the German Research Foundation (DFG: GR 1912/5-1), Federal Ministry of Education and Research Germany, the Humboldt Foundation, and the German Research Foundation.

Study of Health in Pomerania: To HJG German Research Foundation; Federal Ministry of Education and Research Germany; speakers honoraria from Bristol-Myers Squibb, Eli Lilly, Novartis, Eisai, Wyeth, Pfizer, Boehringer Ingelheim, and Servier; and travel funds from Lundbeck, Janssen-Cilag, Eli Lilly, Novartis, AstraZeneca, and SALUS-Institute for Trend-Research and Therapy Evaluation in Mental Health. To HV research grants by Sanofi-Aventis, Biotronik, the Humboldt Foundation, the Federal Ministry of Education and Research (Germany), and the German Research Foundation. All other authors reported no biomedical financial interests or potential conflicts of interest.

Supplementary material cited in this article is available online.

- Farmer A, Harris T, Redman K, Sadler S, Mahmood A, McGuffin P (2000): Cardiff depression study. A sib-pair study of life events and familiarity in major depression. *Br J Psychiatry* 176:150–155.

- Sullivan PF, Neale MC, Kendler KS (2000): Genetic epidemiology of major depression: Review and meta-analysis. *Am J Psychiatry* 157: 1552–1562.
- Breen G, Webb BT, Butler AW, van den Oord EJ, Tozzi F, Craddock N, *et al.* (2011): A genome-wide significant linkage for severe depression on chromosome 3: The depression network study. *Am J Psychiatry* 168:840–847.
- Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, *et al.* (2011): A 3p26–3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families. *Am J Psychiatry* 168:848–852.
- Lopez Leon S, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM (2005): The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: A meta-analysis. *Biol Psychiatry* 57:999–1003.
- Lopez-Leon S, Janssens AC, Gonzalez-Zuloeta Ladd AM, Del-Favero J, Claes SJ, *et al.* (2008): Meta-analyses of genetic studies on major depressive disorder. *Mol Psychiatry* 13:772–785.
- Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, *et al.* (2009): Genome-wide association for major depressive disorder: A possible role for the presynaptic protein piccolo. *Mol Psychiatry* 14: 359–375.
- Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, *et al.* (2010): Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. *Mol Psychiatry* 15: 589–601.
- Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, *et al.* (2011): Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. *Mol Psychiatry* 16: 202–215.
- Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, *et al.* (2011): Genome-wide association study of recurrent early-onset major depressive disorder. *Mol Psychiatry* 16:193–201.
- Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, *et al.* (2010): Genome-wide association study of major recurrent depression in the U.K. population. *Am J Psychiatry* 167:949–957.
- Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F, Breuer R, *et al.* (2010): Genome-wide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. *Biol Psychiatry* 68:578–585.
- Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR, *et al.* (2012): Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. *Mol Psychiatry* 17:36–48.
- Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, *et al.* (2010): Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. *Am J Psychiatry* 167:1254–1263.
- Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, *et al.* (2011): The neuronal transporter gene SLC6A15 confers risk to major depression. *Neuron* 70:252–265.
- Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, *et al.* (2011): Poor replication of candidate genes for major depressive disorder using genome-wide association data. *Mol Psychiatry* 16: 516–532.
- Ayuso-Mateos JL, Nuevo R, Verdes E, Naidoo N, Chatterji S (2010): From depressive symptoms to depressive disorders: The relevance of thresholds. *Br J Psychiatry* 196:365–371.
- Hettema JM, Neale MC, Myers JM, Prescott CA, Kendler KS (2006): A population-based twin study of the relationship between neuroticism and internalizing disorders. *Am J Psychiatry* 163:857–864.
- Kendler KS, Gardner CO Jr (1998): Boundaries of major depression: An evaluation of DSM-IV criteria. *Am J Psychiatry* 155:172–177.
- van der Sluis S, Posthuma D, Nivard MG, Verhage M, Dolan CV (2013): Power in GWAS: Lifting the curse of the clinical cut-off. *Mol Psychiatry* 18:2–3.
- Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, *et al.* (2010): Genome-wide association scan of trait depression. *Biol Psychiatry* 68:811–817.
- Beekman AT, Deeg DJ, Van Limbeek J, Braam AW, De Vries MZ, Van Tilburg W (1997): Criterion validity of the Center for Epidemiologic Studies Depression scale (CES-D): Results from a community-based sample of older subjects in The Netherlands. *Psychol Med* 27:231–235.

23. Harlow SD, Goldberg EL, Comstock GW (1991): A longitudinal study of risk factors for depressive symptomatology in elderly widowed and married women. *Am J Epidemiol* 134:526–538.
24. Kuchibhatla MN, Fillenbaum GG, Hybels CF, Blazer DG (2012): Trajectory classes of depressive symptoms in a community sample of older adults. *Acta Psychiatr Scand* 125:492–501.
25. Gump BB, Matthews KA, Eberly LE, Chang YF (2005): Depressive symptoms and mortality in men: Results from the Multiple Risk Factor Intervention Trial. *Stroke* 36:98–102.
26. Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, Furberg CD (2000): Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. *Circulation* 102:1773–1779.
27. Carmelli D, Swan GE, Kelly-Hayes M, Wolf PA, Reed T, Miller B (2000): Longitudinal changes in the contribution of genetic and environmental influences to symptoms of depression in older male twins. *Psychol Aging* 15:505–510.
28. Jansson M, Gatz M, Berg S, Johansson B, Malmberg B, McClearn GE, *et al.* (2004): Gender differences in heritability of depressive symptoms in the elderly. *Psychol Med* 34:471–479.
29. Choy WC, Lopez-Leon S, Aulchenko YS, Mackenbach JP, Oostra BA, van Duijn CM, Janssens AC (2009): Role of shared genetic and environmental factors in symptoms of depression and body composition. *Psychiatr Genet* 19:32–38.
30. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JJ, *et al.* (2009): Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet* 2:73–80.
31. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. *Am J Epidemiol* 1989;129:687–702.
32. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, *et al.* (1991): The Cardiovascular Health Study: Design and rationale. *Ann Epidemiol* 1:263–276.
33. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP (1975): The Framingham Offspring Study. Design and preliminary data. *Prev Med* 4:518–525.
34. Dawber TR, Meadors GF, Moore FE Jr (1951): Epidemiological approaches to heart disease: The Framingham Study. *Am J Public Health Nations Health* 41:279–281.
35. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, *et al.* (2011): The Rotterdam Study: 2012 objectives and design update. *Eur J Epidemiol* 26:657–686.
36. Shock NW, Greulich RC, Costa PT, Andres R, Lakatta EG, Arenberg D, Tobin JD (1984): *Normal Human Aging: The Baltimore Study of Aging*. Washington, DC: US Government Printing Office.
37. Aulchenko YS, Heutink P, Mackay I, Bertoli-Avella AM, Pullen J, Vaessen N, *et al.* (2004): Linkage disequilibrium in young genetically isolated Dutch population. *Eur J Hum Genet* 12:527–534.
38. Ferrucci L, Bandinelli S, Benvenuti E, Di Iorio A, Macchi C, Harris TB, Guralnik JM (2000): Subsystems contributing to the decline in ability to walk: Bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. *J Am Geriatr Soc* 48:1618–1625.
39. Barker DJ, Osmond C, Forsen TJ, Kajantie E, Eriksson JG (2005): Trajectories of growth among children who have coronary events as adults. *N Engl J Med* 353:1802–1809.
40. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, *et al.* (2002): Multi-ethnic study of atherosclerosis: Objectives and design. *Am J Epidemiol* 156:871–881.
41. Colditz GA, Hankinson SE (2005): The Nurses' Health Study: Lifestyle and health among women. *Nat Rev Cancer* 5:388–396.
42. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS (2005): The Rush Memory and Aging Project: Study design and baseline characteristics of the study cohort. *Neuroepidemiology* 25:163–175.
43. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006): Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology* 66:1837–1844.
44. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, *et al.* (2006): Heritability of cardiovascular and personality traits in 6,148 Sardinians. *PLoS Genet* 2:e132.
45. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J (1993): Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. *J Aging Health* 5:179–193.
46. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, *et al.* (2000): Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. *Hypertension* 36:477–483.
47. Willer CJ, Li Y, Abecasis GR (2010): METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26: 2190–2191.
48. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, *et al.* (2007): PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81:559–575.
49. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson G, *et al.* (2007): Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary applied phenomics. *Am J Epidemiol* 165:1076–1087.
50. Holle R, Hapich M, Lowel H, Wichmann HE, Group MKS (2005): KORA—a research platform for population based health research. *Gesundheitswesen* 67(suppl 1):S19–S25.
51. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, *et al.* (2011): Cohort profile: The Study of Health in Pomerania. *Int J Epidemiol* 40:294–307.
52. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, *et al.* (2001): Study of Health In Pomerania (SHIP): A health examination survey in an east German region: Objectives and design. *Soz Präventivmed* 46: 186–194.
53. Milette K, Hudson M, Baron M, Thombs BD & Canadian Scleroderma Research Group. (2010): Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: Internal consistency reliability, convergent validity and clinical correlates. *Rheumatology (Oxford)* 49: 789–796.
54. Shean G, Baldwin G (2008): Sensitivity and specificity of depression questionnaires in a college-age sample. *J Genet Psychol* 169:281–288.
55. Kopp MS, Falger PR, Appels A, Szedmak S (1998): Depressive symptomatology and vital exhaustion are differentially related to behavioral risk factors for coronary artery disease. *Psychosom Med* 60: 752–758.
56. Wojciechowski FL, Strik JJ, Falger P, Lousberg R, Honig A (2000): The relationship between depressive and vital exhaustion symptomatology post-myocardial infarction. *Acta Psychiatr Scand* 102:359–365.
57. Watanakit K, Williams JE, Schreiner PJ, Hirsch AT, Folsom AR (2005): Association of anger proneness, depression and low social support with peripheral arterial disease: The Atherosclerosis Risk in Communities Study. *Vasc Med* 10:199–206.
58. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, *et al.* (2003): PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification. *Nucleic Acids Res* 31:334–341.
59. Hek K, Mulder CL, Luijendijk HJ, van Duijn CM, Hofman A, Uitterlinden AG, Tiemeier H (2010): The PCLO gene and depressive disorders: Replication in a population-based study. *Hum Mol Genet* 19:731–734.
60. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003): Measuring inconsistency in meta-analyses. *BMJ* 327:557–560.
61. Thompson JR, Attia J, Minelli C (2011): The meta-analysis of genome-wide association studies. *Brief Bioinform* 12:259–269.
62. Gustav Smith J, Newton-Cheh C (2009): Genome-wide association studies in humans. In: DiPetrillo K, editor. *Methods in Molecular Biology. Cardiovascular Genomics: Methods and Protocols*, vol. 573. Seacucus, NJ: Springer, 231–258.
63. Breslau N (1985): Depressive symptoms, major depression, and generalized anxiety: A comparison of self-reports on CES-D and results from diagnostic interviews. *Psychiatry Res* 15:219–229.
64. Hetteema JM (2008): What is the genetic relationship between anxiety and depression? *Am J Med Genet C Semin Med Genet* 148C:140–146.
65. Gillespie NA, Kirk KM, Evans DM, Heath AC, Hickie IB, Martin NG (2004): Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins. *Twin Res* 7:39–53.
66. Demirkan A, Penninx BW, Hek K, Wray NR, Amin N, Aulchenko YS, *et al.* (2011): Genetic risk profiles for depression and anxiety in adult and elderly cohorts. *Mol Psychiatry* 16:773–783.

67. Shafer AB (2006): Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. *J Clin Psychol* 62:123–146.
68. Agrell B, Dehlin O (1989): Comparison of six depression rating scales in geriatric stroke patients. *Stroke* 20:1190–1194.
69. Bernert S, Matschinger H, Alonso J, Haro JM, Brugha TS, Angermeyer MC & ESEMeD / MHEDEA 2000 investigators (2009): Is it always the same? Variability of depressive symptoms across six European countries. *Psychiatry Res* 168:137–144.
70. McClellan J, King MC (2010): Genomic analysis of mental illness: A changing landscape. *JAMA* 303:2523–2524.
71. Zhang J, Chen Y, Zhang K, Yang H, Sun Y, Fang Y, *et al.* (2010): A cis-phase interaction study of genetic variants within the MAOA gene in major depressive disorder. *Biol Psychiatry* 68:795–800.
72. Yang C, Xu Y, Sun N, Ren Y, Liu Z, Cao X, Zhang K (2010): The combined effects of the BDNF and GSK3B genes modulate the relationship between negative life events and major depressive disorder. *Brain Res* 1355:1–6.
73. Zammit S, Owen MJ, Lewis G (2010): Misconceptions about gene-environment interactions in psychiatry. *Evid Based Ment Health* 13:65–68.
74. Glessner JT, Wang K, Sleiman PM, Zhang H, Kim CE, Flory JH, *et al.* (2010): Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. *PLoS One* 5:e15463.
75. Rucker JJ, Breen G, Pinto D, Pedrosa I, Lewis CM, Cohen-Woods S, *et al.* (2011): Genome-wide association analysis of copy number variation in recurrent depressive disorder [published online ahead of print November 1]. *Mol Psychiatry*.